aTyr Pharma, Inc. Stock price

Equities

LIFE

US0021202025

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
1.95 USD -2.50% Intraday chart for aTyr Pharma, Inc. -3.47% +38.30%
Sales 2024 * 2.62M Sales 2025 * 9.26M Capitalization 132M
Net income 2024 * -63M Net income 2025 * -66M EV / Sales 2024 * 50.3 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 14.3 x
P/E ratio 2024 *
-1.96 x
P/E ratio 2025 *
-2.04 x
Employees 58
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.7%
More Fundamentals * Assessed data
Dynamic Chart
RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier MT
Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis CI
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (LIFE) ATYR PHARMA Posts Q3 Revenue $353,000 MT
Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect?? Study of Efzofitimod in Patients with Ssc-Ild CI
Top Premarket Gainers MT
Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes CI
ATyr Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Piper Sandler Adjusts Price Target on aTyr Pharma to $20 From $13, Maintains Overweight Rating MT
North American Morning Briefing : Fed Hawks Hit -2- DJ
Oppenheimer Downgrades aTyr Pharma to Perform From Outperform, Removes $17 Price Target MT
ATyr Pharma, Inc.(NasdaqCM:LIFE) added to Russell 3000E Growth Index CI
More news
1 day-2.50%
1 week-3.47%
Current month+1.56%
1 month+2.63%
3 months+32.65%
6 months+22.64%
Current year+38.30%
More quotes
1 week
1.85
Extreme 1.85
2.09
1 month
1.55
Extreme 1.55
2.15
Current year
1.39
Extreme 1.39
2.15
1 year
1.08
Extreme 1.0801
2.70
3 years
1.08
Extreme 1.0801
13.10
5 years
1.08
Extreme 1.0801
13.10
10 years
1.08
Extreme 1.0801
396.06
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 16-03-29
Director of Finance/CFO 63 18-07-29
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Founder 83 05-09-07
Chairman 57 17-04-09
Director/Board Member 70 05-08-31
More insiders
Date Price Change Volume
24-03-28 1.95 -2.50% 726,167
24-03-27 2 +4.44% 1,200,945
24-03-26 1.915 -0.26% 282,116
24-03-25 1.92 -1.54% 338,042
24-03-22 1.95 -3.47% 355,219

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.95 USD
Average target price
25.25 USD
Spread / Average Target
+1,194.87%
Consensus
  1. Stock
  2. Equities
  3. Stock aTyr Pharma, Inc. - Nasdaq